外周T细胞淋巴瘤分子亚群中致癌通路的遗传驱动因素
该研究对外周T细胞淋巴瘤(PTCL)中血管免疫母细胞性T细胞淋巴瘤(AITL)和PTCL-非特指型(PTCL-NOS)的基因表达谱定义分子亚群(PTCL-GATA3和PTCL-TBX21),通过拷贝数分析和靶向测序揭示各亚群独特的拷贝数异常和致癌通路,并发现CDKN2A缺失在PTCL-NOS及PTCL-GATA3中具有预后意义,为未来临床试验提供生物学依据。
要点
- PTCL-GATA3亚群基因组复杂度更高,靶向CDKN2A/B-TP53轴和PTEN-PI3K通路。
- PTCL-TBX21亚群拷贝数异常较少,主要靶向细胞毒效应基因,富集DNA甲基化调控基因突变。
- AITL基因组复杂度较低,chr5和chr21共获得与IDH2 R172突变显著相关。
核心结论
- 基因表达谱定义的新型PTCL亚群可能通过不同的遗传途径演化,并为未来临床试验中可研究的疗法提供生物学依据。
研究设计与样本
- 研究对AITL和PTCL-NOS的基因表达谱定义分子亚群进行基因组拷贝数分析和靶向测序,样本量原文未报告。
主要发现
- PTCL-GATA3亚群基因组复杂度更高,以靶向CDKN2A/B-TP53轴和PTEN-PI3K通路的肿瘤抑制基因频繁丢失或突变为特征,并出现STAT3和MYC的共获得/扩增。
- PTCL-TBX21亚群拷贝数异常较少,主要靶向细胞毒效应基因,并富集DNA甲基化调控基因突变。
- AITL基因组复杂度低于其他PTCL实体,chr5和chr21共获得与IDH2 R172突变显著相关,无IDH2突变病例中拷贝数丢失富集于PI3K-AKT-mTOR信号调控基因。
关键数值与推荐
- PTCL-GATA3和PTCL-TBX21为基因表达谱定义的PTCL-NOS分子亚群,AITL和PTCL-NOS占PTCLs的>50%。
- CDKN2A缺失作为单一实体在PTCL-NOS中及在PTCL-GATA3亚群中显示预后意义。
- AITL中chr5和chr21共获得与IDH2 R172突变显著相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Peripheral T-cell lymphoma (PTCL) is a group of complex clinicopathological entities, often associated with an aggressive clinical course. Angioimmunoblastic T-cell lymphoma (AITL) and PTCL-not otherwise specified (PTCL-NOS) are the 2 most frequent categories, accounting for >50% of PTCLs. Gene expression profiling (GEP) defined molecular signatures for AITL and delineated biological and prognostic subgroups within PTCL-NOS (PTCL-GATA3 and PTCL-TBX21). Genomic copy number (CN) analysis and targeted sequencing of these molecular subgroups revealed unique CN abnormalities (CNAs) and oncogenic pathways, indicating distinct oncogenic evolution. PTCL-GATA3 exhibited greater genomic complexity that was characterized by frequent loss or mutation of tumor suppressor genes targeting the CDKN2A /B-TP53 axis and PTEN-PI3K pathways. Co-occurring gains/amplifications of STAT3 and MYC occurred in PTCL-GATA3. Several CNAs, in particular loss of CDKN2A, exhibited prognostic significance in PTCL-NOS as a single entity and in the PTCL-GATA3 subgroup. The PTCL-TBX21 subgroup had fewer CNAs, primarily targeting cytotoxic effector genes, and was enriched in mutations of genes regulating DNA methylation. CNAs affecting metabolic processes regulating RNA/protein degradation and T-cell receptor signaling were common in both subgroups. AITL showed lower genomic complexity compared with other PTCL entities, with frequent co-occurring gains of chromosome 5 (chr5) and chr21 that were significantly associated with IDH2 R172 mutation. CN losses were enriched in genes regulating PI3K-AKT-mTOR signaling in cases without IDH2 mutation. Overall, we demonstrated that novel GEP-defined PTCL subgroups likely evolve by distinct genetic pathways and provided biological rationale for therapies that may be investigated in future clinical trials.
引用
- Heavican TB, Bouska A, Yu J, et al. Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma. Blood. 2019. PMID: 30782609. doi:10.1182/blood-2018-09-872549
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。